

## CLINICAL PRACTICE

## Hidradenitis Suppurativa

Gregor B.E. Jemec, M.D., D.M.Sc.

*This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.*

**A 36-year-old woman has recurrent boils under both arms and in the groin. They flare premenstrually, causing pain, suppuration, and an offensive odor. Scarring has developed in the groin area, and chronically draining sinus tracts are interspersed with normal skin. Treatment with short courses of antibiotics or with incision and drainage has had no apparent effect, and she has become socially isolated because of embarrassment about her condition. How would you manage this case?**

## THE CLINICAL PROBLEM

From the Department of Dermatology, Roskilde Hospital, Roskilde, Denmark; and Faculty of Health Sciences, University of Copenhagen, Copenhagen. Address reprint requests to Dr. Jemec at the Department of Dermatology, Roskilde Hospital, Roskilde DK-4000, Denmark, or at [gjb@regionsjaelland.dk](mailto:gjb@regionsjaelland.dk).

N Engl J Med 2012;366:158-64.

Copyright © 2012 Massachusetts Medical Society.



An audio version  
of this article  
is available at  
[NEJM.org](http://NEJM.org)

Hidradenitis suppurativa<sup>1,2</sup> is a chronic, recurrent inflammatory disease affecting skin that bears apocrine glands. It usually develops after puberty, manifested as painful, deep-seated, inflamed lesions, including nodules, sinus tracts, and abscesses. In most patients, flares are accompanied by increased pain and suppuration at varying intervals, often occurring premenstrually in women. If untreated, the flares subside within 7 to 10 days.<sup>3</sup>

European studies have suggested that hidradenitis suppurativa is not a rare disease. A French community-based study,<sup>4</sup> in which persons older than 15 years of age responded to a validated questionnaire (with a positive predictive value of 85 to 89%), showed a point prevalence at 1 year of 1%. Studies of young adults (18 to 33 years of age) undergoing screening for sexually transmitted diseases have shown point prevalences of up to 4%.<sup>5</sup>

Women are more frequently affected than men (female:male ratio, 3:1) and appear to be more likely to have genitofemoral lesions. The condition most commonly develops in persons in their early 20s, although the onset has been described in prepubertal children and in postmenopausal women as well.<sup>4,6</sup> The prevalence of the disease appears to decline at an age of more than 50 years.<sup>4</sup>

About one third of patients with hidradenitis suppurativa report a family history of the disease, and affected families with an autosomal dominant mode of inheritance have been identified. In a small number of cases in which hidradenitis suppurativa is accompanied by severe acne and perifolliculitis capitis, the disease has been linked to chromosome 1p21.1–1q25.3 and mutations of the  $\gamma$ -secretase complex.<sup>7</sup> Studies have not shown associations between HLA antigens and hidradenitis suppurativa.<sup>8</sup>

Cigarette smoking is a recognized risk factor for both the development of hidradenitis suppurativa and severe disease.<sup>9</sup> Obesity is also a risk factor; the majority of patients are overweight, and both body-mass index and tobacco smoking have been directly correlated with the severity of this condition.<sup>10</sup>

The disease has a substantial negative effect on the quality of life of affected persons, as compared with the general population or with patients who have other chronic skin conditions (e.g., psoriasis or eczematous dermatitis).<sup>11-13</sup> Rates of sick

## KEY CLINICAL POINTS

## HIDRADENITIS SUPPURATIVA

- Hidradenitis suppurativa is a chronic, recurrent inflammatory disease affecting skin that bears apocrine glands.
- It is manifested as painful, deep-seated, inflamed lesions, including nodules, sinus tracts, and abscesses, and is estimated to affect 1% of the population.
- A long delay in diagnosis is common, since the disease is often mistaken for a simple infection.
- Lesions treated with incision and drainage routinely recur.
- Few randomized trials have been carried out to guide care, but observational data suggest that many patients have improvement after treatment with antibiotics; a tetracycline or a combination of clindamycin and rifampin is often used.
- For more severe disease, treatment may involve immunosuppressive agents such as inhibitors of tumor necrosis factor  $\alpha$ , although results of randomized trials have been inconsistent.
- For recalcitrant lesions, complete removal by surgical excision or laser therapy often results in local clearing.

leave from work are higher and self-reported general health is lower among patients with hidradenitis suppurativa than in the general population.<sup>14</sup>

Conditions reported to be associated with hidradenitis suppurativa include severe acne, acne conglobata, and pilonidal cysts, although it is possible that these conditions are misdiagnosed in patients with hidradenitis suppurativa.<sup>1</sup> Data from an epidemiologic study suggested a 50% increase in the risk of cancer of any kind in patients with hidradenitis suppurativa, as compared with the general population<sup>15</sup>; specific cancers reported to occur more frequently in these patients included squamous-cell carcinoma (e.g., Marjolin's ulcers associated with chronic lesions of hidradenitis suppurativa, primarily of the buttocks), buccal cancer, and hepatocellular cancer. However, this study did not adjust for status with respect to cigarette smoking, and it is likely that the observed associations were confounded by smoking — a recognized risk factor for both hidradenitis suppurativa and these diseases.

The frequency of hidradenitis suppurativa has been reported to be increased among patients with Crohn's disease, affecting 17% of such patients, according to one report. A relationship between the two conditions is supported by clinical, histologic, and epidemiologic similarities, such as sinus tracts, granulomatous inflammation, scarring, and onset after puberty.<sup>16</sup> Arthritis (rheumatoid factor–negative and HLA-B27–negative) is also more frequent among patients with hidradenitis suppurativa than in the general popu-

lation and usually involves the peripheral joints, often in an asymmetric manner.<sup>1</sup>

## PATHOGENESIS

The pathogenesis of hidradenitis suppurativa remains unclear. Histologic studies suggest that it is a multifocal disease, in which atrophy of the sebaceous glands is followed by an early lymphocytic inflammation and hyperkeratosis of the pilosebaceous unit and, later, by hair-follicle destruction and granuloma formation.<sup>17-22</sup> It is speculated that subsequent healing processes (not well defined) produce scarring and sinus tract formation — processes that are exacerbated by the impaired mechanical integrity of the sinus tract epithelium.<sup>22</sup> Recent investigations suggest that the interleukin-12–interleukin-23 pathway and tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) are involved in the pathogenesis of hidradenitis suppurativa, supporting the proposition that it is an immune or inflammatory disorder.<sup>23,24</sup>

## STRATEGIES AND EVIDENCE

## EVALUATION

The diagnosis of hidradenitis suppurativa is generally made clinically. On physical examination, one may see characteristic inflamed and noninflamed nodules; draining and nondraining sinus tracts; and abscesses in the axillary, inguinal, and anogenital regions. The lesions occasionally extend beyond these areas and appear around the anus, on the buttock, or on the breast in females.



**Figure 1. Hurley Stages of Lesions in Hidradenitis Suppurativa.**

Although the examples shown here are of hidradenitis suppurativa of the axillary area, the same principles of the Hurley staging system apply to the disease when it affects other locations. Panel A shows stage I disease, which is localized and includes the formation of single or multiple abscesses, without sinus tracts and scarring. (Courtesy of Jurr Boer, M.D.) Panel B shows stage II disease, which is characterized by recurrent abscesses, with sinus tract formation and scarring, occurring as either single lesions or multiple, widely separated lesions. Panel C shows stage III disease, which includes diffuse or nearly diffuse involvement of the affected region, with multiple interconnected tracts and abscesses across the entire area.

The nodules are located in the deeper dermis and are rounded rather than having the pointed, purulent appearance of simple boils (Fig. 1, 2, and 3). Secondary lesions such as pyogenic granulomas in sinus tract openings, plaquelike induration, ropelike scars, and giant multiheaded comedones may also be found.

In selected cases, additional testing may be helpful. Biopsies and bacterial cultures are indicated only in atypical or refractory cases. Routine bacteriologic studies of the lesions in hidradenitis suppurativa are most frequently negative, although flares may be associated with superinfection involving a range of bacteria, including *Staphylococcus aureus*.<sup>25,26</sup> If extensive surgery is planned, ultrasonography may help in the preoperative assessment by identifying subclinical extension of the lesions.<sup>27</sup>

Despite the typical presentation, the disease is often diagnosed only after a considerable delay; in one study, the median delay was 12 years.<sup>28</sup> Many cases are misdiagnosed as common boils and treated with lancing or short-term antibiotic therapy — approaches that may seem effective at first (since flares tend to subside spontaneously after a week) but ultimately fail.

Assessment of the severity of the disease is helpful in guiding treatment and is generally based on the Hurley staging system (Fig. 1).<sup>29</sup> In the majority of cases, patients have stage II disease at the time of diagnosis, presumably reflecting diagnostic delay. Only about 1% of patients have progression to stage III disease.

#### MEDICAL MANAGEMENT AND LIFESTYLE MEASURES

Stage I (localized) disease is usually managed with topical therapy, whereas systemic therapy is recommended for more widespread or severe disease. Since data from randomized trials are limited, choices among treatments are generally guided by the results in case series and by clinical experience.

In a small, randomized, placebo-controlled trial involving patients who appeared by description to have mild disease (although no formal staging was performed), topical administration of clindamycin (10 mg per milliliter twice daily) was found to reduce the number of abscesses, nodules, and pustules at monthly evaluations during a 3-month course of treatment.<sup>30</sup> Clinical experience has also supported the use of intralesional injections of glucocorticoids (e.g., triamcinolone, 2 to 5 mg)

for individual lesions,<sup>1</sup> although this therapy has not been well studied.

When topical treatment is insufficient, oral antibiotics (often those with antiinflammatory and immunomodulatory properties<sup>31</sup>) are commonly used. This approach is likewise based largely on clinical experience; one small, randomized trial in which oral tetracycline at a dose of 500 mg twice a day was compared with topical clindamycin given twice a day, each for 3 months, failed to show superiority of the oral therapy.<sup>32</sup> Alternatively, combination antibiotic therapy is used, although data from randomized trials comparing this approach with single-agent oral therapy or topical therapy are lacking. In two case series involving a total of 190 patients with mild-to-severe disease who were treated with both clindamycin and rifampin (each typically given at a dose of 300 mg twice daily), scores for disease severity were reduced by 50%, as compared with baseline, and quality of life improved significantly.<sup>33,34</sup> The results appeared to be similar for patients who received lower doses, and the authors speculated that the antiinflammatory effects of these drugs or natural variations in severity may play a role. However, these studies lacked controls and blinding; randomized trials are needed to confirm efficacy (including combined therapy vs. single-agent therapy) and to guide decisions about dosing and the duration of therapy.

In women with hidradenitis suppurativa, antiandrogens are sometimes used, although, as with other treatments, this treatment is based largely on anecdotal evidence.<sup>35,36</sup> A 1-year, double-blind, crossover trial (with crossover after 6 months of treatment) involving 24 premenopausal women compared two regimens: ethinyl estradiol given from days 5 through 25 of the menstrual cycle plus cyproterone acetate given on days 5 through 14 versus the combination of ethinyl estradiol and cyproterone acetate given on cycle days 5 through 25. The benefits were found to be similar with the two regimens, as assessed by reductions in the frequencies of lumps and boils, the quantity of discharge, and the degree of pain and discomfort; overall, in 12 of the women (50%), the disease improved or cleared completely with either regimen.<sup>36</sup>

Case series have suggested a lack of benefit from isotretinoin.<sup>37,38</sup> For example, among 48 patients treated with isotretinoin (mean dose, 0.6 mg



**Figure 2. Involvement of the Genitalia in a Woman with Hurley Stage III Disease.**

Genitofemoral lesions are common in patients with hidradenitis suppurativa, especially in women.

per kilogram of body weight) for at least 4 months, fewer than one fourth had clearing of lesions, and most of the patients who had a response to the treatment had mild disease.<sup>37</sup>

In severe cases of hidradenitis suppurativa, systemic immunosuppressive agents have been used. Case reports have described rapid control of the disease in patients treated with cyclosporine (3 to 6 mg per kilogram).<sup>39,40</sup> More recently, TNF- $\alpha$  inhibitors have been studied in randomized trials, with inconsistent results. In a randomized, double-blind, 8-week trial, infliximab (5 mg per kilogram) given at weeks 0, 2, and 6, as compared with placebo, resulted in a significant reduction in a composite score reflecting the extent of disease and ratings of drainage and pain. However, another randomized, double-blind, placebo-controlled trial failed to show a significant benefit of etanercept (50 mg twice weekly) with the use of a physician's global assessment scale.<sup>41,42</sup> In a third randomized, controlled trial, adalimumab (40 mg given every other week after a loading dose of 80 mg) resulted in significant improvement on the basis of a score that reflected the extent and severity of disease at 6 weeks, but



**Figure 3. Involvement of the Buttocks in a Man with Hurley Stage III Disease.**

The disease may also involve the buttocks, in addition to the axillae and genitofemoral folds, which are the pathognomonic locations.

this benefit was not maintained at 12 weeks (the primary outcome of the trial).<sup>43</sup>

Since smoking and obesity are associated with severe hidradenitis suppurativa,<sup>10</sup> affected patients should refrain from tobacco use and control their weight, although data are not available from randomized trials assessing the effects of such restrictions. Case reports describe the development or exacerbation of lesions as a result of mechanical stress, so rubbing of the affected skin should also be avoided.<sup>1</sup>

#### **SURGICAL MANAGEMENT**

In cases of individual scarred lesions or stage III disease, clinical experience suggests that surgical options offer the best chances for cure. For milder disease, topical or systemic therapy should be tried first because of the multifocal nature of the disease, with surgery reserved for unresponsive lesions. Scarring is not amenable to medical treatment, so the presence of considerable scarring should be considered a relative indication for surgery. Incision with drainage is discouraged, since recurrence is the norm.<sup>44</sup> Furthermore, inflamed, nonfluctuating nodules do not drain readily.

Surgery can be either limited or extensive. Limited surgical interventions include exteriorization of sinus tracts (i.e., surgical removal of the “roof” of an abscess, cyst, or sinus tract, with the “floor” left intact for more rapid healing) and localized excision.<sup>45</sup> Observational data indicate a substantially lower risk of recurrence among pa-

tients who undergo more extensive excision of all hair-bearing skin in the affected region (e.g., the axilla) than among those who undergo excision of inflamed lesions only<sup>46</sup>; this outcome was attributed to incomplete removal of diseased tissue when the latter procedure is used.

#### **LASER AND RADIATION THERAPY**

Laser therapy has recently been adopted for use in the treatment of hidradenitis suppurativa. In one randomized, controlled trial, monthly treatment with a neodymium:yttrium–aluminum–garnet laser for 3 months in patients with stage II or stage III disease resulted in a significant reduction in disease severity at follow-up a month after therapy was completed (based on a 65% reduction according to a validated disease-severity scoring system), as compared with a reduction of about 7% with topical antibiotic therapy (benzoyl peroxide 10% or clindamycin 1%).<sup>47</sup> Although data from trials comparing surgical techniques with laser therapy are lacking, the use of healing by secondary intention (i.e., leaving the wound open to heal under a dressing) is widely advocated. In a case series of 24 lesions treated with a carbon dioxide laser and left to heal by secondary intention, the authors reported only two recurrences after a mean follow-up of 27 months.<sup>48</sup> Likewise, another case series showed a low rate of local recurrence for lesions treated with a carbon dioxide laser, whereas flares in other, untreated regions were common during follow-up.<sup>49</sup>

The use of external-beam radiation therapy has also been described. In a review of 231 cases treated with a total dose of 3 to 8 Gy (175-kV orthovoltage therapy unit, with a 0.5-mm copper filter), active lesions resolved in about one third of the patients treated. However, this approach is rarely used because of concern that the long-term risks may outweigh its benefits.<sup>50</sup>

#### **AREAS OF UNCERTAINTY**

There is a paucity of data from randomized, controlled trials to guide decisions about therapy in patients with hidradenitis suppurativa. Controlled trials are needed to compare the effects of different regimens and durations of antibiotic therapy, to assess the efficacy of combination therapy as compared with monotherapy, and to compare antibiotic treatment with immunosuppressive treat-

ment in severe cases. Similarly, there is a need for a systematic comparison of surgical techniques (e.g., laser vs. conventional surgery) and approaches to postprocedure management (open healing vs. primary closure or skin grafting).

#### GUIDELINES

No formal guidelines are currently available for the management of hidradenitis suppurativa.

#### CONCLUSIONS AND RECOMMENDATIONS

The patient described in the vignette presented with a history of recurrent lesions that are consistent with stage II hidradenitis suppurativa. Management should be guided by disease severity. For stage I, characterized by mild, nonscarring disease, limited clinical trial data support the efficacy of topical clindamycin; although data are lacking to support the use of intralesional triam-

cinolone, clinical experience suggests that it may be useful for some isolated lesions. Case series suggest that scarred lesions are best treated with wide excision or evaporation with the use of a carbon dioxide laser. More extensive and severe disease requires systemic treatment. For stage II disease, as seen in the patient described in the vignette, I would try combination antibiotic therapy (clindamycin and rifampin, 300 mg twice daily for 6 months), since it has appeared to be effective in case series and clinical practice, although the combined regimen has not been compared with either of these agents alone or with other treatments in randomized clinical trials.

Dr. Jemec reports receiving consulting fees from Abbott Laboratories, Merck, Pfizer, and Dumex-Alpha, lecture fees from Galderma and Pfizer, and grant support from Abbott Laboratories, Photocure, and LEO Pharma; receiving equipment on loan from Michelson Diagnostics; and receiving reimbursement for travel expenses from Abbott Laboratories, Galderma, and Photocure. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

#### REFERENCES

- Jemec GBE, Revuz J, Leyden JJ, eds. *Hidradenitis suppurativa*. Berlin: Springer Verlag, 2006.
- Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa? *Exp Dermatol* 2008;17:455-72.
- von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. *J Eur Acad Dermatol Venereol* 2000;14:389-92.
- Revuz JE, Canoui-Poitaine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. *J Am Acad Dermatol* 2008;59:596-601.
- Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. *J Am Acad Dermatol* 1996;35:191-4.
- Palmer RA, Keefe M. Early-onset hidradenitis suppurativa. *Clin Exp Dermatol* 2001;26:501-3.
- Wang B, Yang W, Wen W, et al. Gamma-secretase gene mutations in familial acne inversa. *Science* 2010;330:1065.
- Lapins J, Olerup O, Emtestam L. No human leukocyte antigen-A, -B or -DR association in Swedish patients with hidradenitis suppurativa. *Acta Derm Venereol* 2001;81:28-30.
- König A, Lehmann C, Rempel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. *Dermatology* 1999;198:261-4.
- Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. *Br J Dermatol* 2009;161:831-9.
- Jemec GB, Heidenheim M, Nielsen NH. Hidradenitis suppurativa — characteristics and consequences. *Clin Exp Dermatol* 1996;21:419-23.
- Matusiak Ł, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. *J Am Acad Dermatol* 2010;62:706-8.
- Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J, Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. *J Am Acad Dermatol* 2007;56:621-3.
- Jemec GB, Heidenheim M, Nielsen NH. A case-control study of hidradenitis suppurativa in an STD population. *Acta Derm Venereol* 1996;76:482-3.
- Lapins J, Ye W, Nyren O, Emtestam L. Incidence of cancer among patients with hidradenitis suppurativa. *Arch Dermatol* 2001;137:730-4.
- van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. *Br J Dermatol* 2010;162:195-7.
- Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. *Br J Dermatol* 1990;122:763-9.
- Jemec GB, Hansen U. Histology of hidradenitis suppurativa. *J Am Acad Dermatol* 1996;34:994-9.
- von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. *Exp Dermatol* 2010;19:533-7.
- Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa: a clinicopathological study of early lesions. *Br J Dermatol* 1996;135:721-5.
- Kamp S, Fiehn AM, Stenderup K, et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. *Br J Dermatol* 2011;164:1017-22.
- Kurokawa I, Nishijima S, Kusumoto K, Senzaki H, Shikata N, Tsubura A. Immunohistochemical study of cytokeratins in hidradenitis suppurativa (acne inversa). *J Int Med Res* 2002;30:131-6.
- Matusiak Ł, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? *Acta Derm Venereol* 2009;89:601-3.
- Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. *J Am Acad Dermatol* 2011;65:790-8.
- Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the

- most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. *Br J Dermatol* 1999;140:90-5.
26. Jemec GB, Faber M, Gutschik E, Wendelboe P. The bacteriology of hidradenitis suppurativa. *Dermatology* 1996;193:203-6.
27. Wortsman X, Jemec GB. Real-time compound imaging ultrasound of hidradenitis suppurativa. *Dermatol Surg* 2007;33:1340-2.
28. Mebazaa A, Ben Hadid R, Cheikh Rouhou R, et al. Hidradenitis suppurativa: a disease with male predominance in Tunisia. *Acta Dermatovenereol Alp Panonica Adriat* 2009;18:165-72.
29. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH Jr, eds. *Dermatologic surgery: principles and practice*. 2nd ed. New York: Marcel Dekker, 1996:623-45.
30. Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. *Int J Dermatol* 1983;22:325-8.
31. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics; biological mechanisms. *Respiration* 2011;81:67-74.
32. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. *J Am Acad Dermatol* 1998;39:971-4.
33. Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. *Dermatology* 2009;219:148-54.
34. van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. *Dermatology* 2009;219:143-7.
35. Sawers RS, Randall VA, Ebling FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. *Br J Dermatol* 1986;115:269-74.
36. Mortimer PS, Dawber RP, Gales MA, Moore RA. A double-blind controlled crossover trial of cyproterone acetate in females with hidradenitis suppurativa. *Br J Dermatol* 1986;115:263-8.
37. Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. *J Am Acad Dermatol* 1999;40:73-6.
38. Soria A, Canoui-Poitrine F, Wolkenstein P, et al. Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment. *Dermatology* 2009;218:134-5.
39. Buckley DA, Rogers S. Cyclosporin-responsive hidradenitis suppurativa. *J R Soc Med* 1995;88:289P-290P.
40. Rose RF, Goodfield MJ, Clark SM. Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin. *Clin Exp Dermatol* 2006;31:154-5.
41. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. *J Am Acad Dermatol* 2010;62:205-17.
42. Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. *Arch Dermatol* 2010;146:501-4.
43. Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. *Br J Dermatol* 2011;165:391-8.
44. Ritz JP, Runkel N, Haier J, Buhr HJ. Extent of surgery and recurrence rate of hidradenitis suppurativa. *Int J Colorectal Dis* 1998;13:164-8.
45. van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. *J Am Acad Dermatol* 2010;63:475-80.
46. Mandal A, Watson J. Experience with different treatment modules in hidradenitis suppurativa: a study of 106 cases. *Surgeon* 2005;3:23-6.
47. Tierney E, Mahmoud BH, Hexsel C, Ozog D, Hamzavi I. Randomized controlled trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. *Dermatol Surg* 2009;35:1188-98.
48. Lapins J, Marcusson JA, Emtestam L. Surgical treatment of chronic hidradenitis suppurativa: CO2 laser stripping-secondary intention technique. *Br J Dermatol* 1994;131:551-6.
49. Lapins J, Sartorius K, Emtestam L. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. *J Am Acad Dermatol* 2002;47:280-5.
50. Fröhlich D, Baaske D, Glatzel M. Radiotherapy of hidradenitis suppurativa — still valid today? *Strahlenther Onkol* 2000;176:286-9. (In German.)

Copyright © 2012 Massachusetts Medical Society.

**EARLY JOB ALERT SERVICE AVAILABLE AT THE NEJM CAREERCENTER**

Register to receive weekly e-mail messages with the latest job openings that match your specialty, as well as preferred geographic region, practice setting, call schedule, and more. Visit the NEJM CareerCenter at [NEJMjobs.org](http://NEJMjobs.org) for more information.